ReviewArthritis research & therapy2010
The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis.
Review in Arthritis research & therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 151 citations in OpenAlex.
- Pooled it
- The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.Arthritis research & therapy · 2018Trial
- Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.Annals of the rheumatic diseases · 2016Trial
- Combined diagnostic value of rheumatoid arthritis-specific citrullinated protein, haemoglobin-to-red cell distribution width ratio, and anti-CCP antibody in rheumatoid arthritis.Annals of medicine · 2026Article
- Refining serological scores in rheumatoid arthritis classification: an international study.RMD open · 2026Article
- [Quality management in the rheumatology laboratory].Zeitschrift fur Rheumatologie · 2026Article
- Rheumatoid Arthritis: A Comprehensive Review of Etiology, Pathophysiology, and Innovative Therapeutic Advancements.Current pharmaceutical design · 2026Review
- Antigen-driven T cell responses in rheumatic diseases: insights from T cell receptor repertoire studies.Nature reviews. Rheumatology · 2025Review
- Impact of Likelihood Ratios of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody in Clinical Diagnosis of Rheumatoid Arthritis by Two Available Platforms.Diagnostics (Basel, Switzerland) · 2025Article
- Integrative multi-omic profiling in blood reveals distinct immune and metabolic signatures between ACPA-negative and ACPA-positive rheumatoid arthritis.Frontiers in immunology · 2025Article
- Anti-citrullinated protein antibody detection by hemagglutination.Rheumatology advances in practice · 2025Article
- Galangin: A Promising Flavonoid for the Treatment of Rheumatoid Arthritis-Mechanisms, Evidence, and Therapeutic Potential.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Antigen-specific Fab profiling achieves molecular-resolution analysis of human autoantibody repertoires in rheumatoid arthritis.Nature communications · 2024Article
- Citrullination and the protein code: crosstalk between post-translational modifications in cancer.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023Review
- PADs and NETs in digestive system: From physiology to pathology.Frontiers in immunology · 2023Review
- T cell Repertoire Profiling and the Mechanism by which HLA-B27 Causes Ankylosing Spondylitis.Current rheumatology reports · 2022Review
- Diabetes-Related Complications and Costs in Medicare Beneficiaries with Comorbid Rheumatoid Arthritis and Diabetes Treated with Abatacept Versus Other Targeted DMARDs.Rheumatology and therapy · 2022Article
- Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells.International journal of molecular sciences · 2022Review
- Impact of autoimmune serology test results on RA classification and diagnosis.Journal of translational autoimmunity · 2022Article
- Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications.Arthritis research & therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The presence or absence of antibodies to citrullinated peptides/proteins (ACPA) is an important parameter that helps a clinician set a diagnosis of early rheumatoid arthritis and, hence, initiate treatment. There are several commercial tests available to measure ACPA levels, although it can be difficult to decide what the best test for a given clinical question is. We analyzed literature data in which the diagnostic and other properties of various ACPA tests are compared. The results show that for diagnostic purposes the CCP2 test has the highest specificity, the highest sensitivity in stratified studies and the highest positive predictive value. For the prediction of future joint destruction the CCP2, MCV, and CCP3 tests may be used. The ability to predict the likelihood of not achieving sustained disease-modifying antirheumatic drug-free remission was highest for the CCP2 test. Finally, the levels of anti-CCP2 and anti-CCP3 (and possibly anti-mutated citrullinated vimentin) in rheumatoid arthritis patients are not significantly influenced by TNFalpha blocking agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.